Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.

Article  CAS  PubMed  Google Scholar 

Kim ES. Letermovir: first global approval. Drugs. 2018;78:147–52.

Article  CAS  PubMed  Google Scholar 

Wang YH, Chen D, Hartmann G, Cho CR, Menzel K. PBPK modeling strategy for predicting complex drug interactions of letermovir as a perpetrator in support of product labeling. Clin Pharmacol Ther. 2019;105:515–23.

Article  CAS  PubMed  Google Scholar 

Nakashima T, Inamoto Y, Fukushi Y, Doke Y, Hashimoto H, Fukuda T, et al. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation. Int J Hematol. 2021;113:872–6.

Article  CAS  PubMed  Google Scholar 

Suetsugu K, Ikesue H, Miyamoto T, Shiratsuchi M, Yamamoto-Taguchi N, Tsuchiya Y, et al. Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2017;105:361–8.

Article  CAS  PubMed  Google Scholar 

Guidelines on TDM of immunosuppressive drugs in organ transplantation. Kanehara Publishing Ltd: Japan. 2014; 1st edn: p 31

Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

Article  CAS  PubMed  Google Scholar 

Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730–44.

Article  CAS  PubMed  Google Scholar 

Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation. 1996;61:1268–72.

Article  CAS  PubMed  Google Scholar 

Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther. 1997;62:41–9.

Article  CAS  PubMed  Google Scholar 

Nakashima T, Inamoto Y, Aoki J, Ito A, Tanaka T, Kim SW, et al. Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal. Int J Hematol. 2022;115:158–62.

Article  CAS  PubMed  Google Scholar 

Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol. 1999;141(56):26–32.

Article  PubMed  Google Scholar